Article Information
History
- July 22, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Helen Ward, PhD1,2,3,4,*,
- Christina Atchison, PhD1,
- Matt Whitaker, MSc1,
- Christl A Donnelly, ScD1,2,5,
- Steven Riley, PhD1,2,
- Deborah Ashby, PhD1,
- Ara Darzi, PhD4,6,
- Wendy S Barclay, PhD7,
- Graham Cooke, PhD3,4,7,
- Paul Elliott, PhD1,3,4,8,9,10,
- for the REACT study team
- 1School of Public Health, Imperial College London, UK
- 2MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, UK
- 3Imperial College Healthcare NHS Trust, UK
- 4National Institute for Health Research Imperial Biomedical Research Centre, UK
- 5Department of Statistics, University of Oxford, UK
- 6Institute of Global Health Innovation at Imperial College London, UK
- 7Department of Infectious Disease, Imperial College London, UK
- 8MRC Centre for Environment and Health, School of Public Health, Imperial College London, UK
- 9Health Data Research (HDR) UK London at Imperial College London, UK
- 10UK Dementia Research Institute at Imperial College London, UK
- ↵*Corresponding authors: Prof Helen Ward, h.ward{at}imperial.ac.uk, +44 20 75 94 33 03; Prof Paul Elliott, p.elliott{at}imperial.ac.uk
Posted July 22, 2021.
Increasing SARS-CoV-2 antibody prevalence in England at the start of the second wave: REACT-2 Round 4 cross-sectional study in 160,000 adults
